ISDA

Deposition Date 2021-06-02

Release Date 2021-09-01

Last Version Date 2023-10-18

Entry Detail

PDB ID:

7N3U

Keywords:

TRANSFERASE

Title:

Crystal structure of human WEE1 kinase domain in complex with ZN-c3

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli BL21

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.65 Å

R-Value Free:

0.26

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Wee1-like protein kinase
Gene (Uniprot):WEE1
Chain IDs:A
Chain Length:285
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P30291 Pfam ID:PF00069 EC:2.7.10.2

Ligand Molecules

05J

Primary Citation

Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer.

Huang, P.Q, Boren, B.C, Hegde, S.G, Liu, H, Unni, A.K, Abraham, S, Hopkins, C.D, Paliwal, S, Samatar, A.A, Li, J, Bunker, K.D.Show

J.Med.Chem. 64 13004 13024 (2021)

PMID: 34423975 DOI: 10.1021/acs.jmedchem.1c01121

Abstact

Wee1 inhibition has received great attention in the past decade as a promising therapy for cancer treatment. Therefore, a potent and selective Wee1 inhibitor is highly desirable. Our efforts to make safer and more efficacious Wee1 inhibitors led to the discovery of compound 16, a highly selective Wee1 inhibitor with balanced potency, ADME, and pharmacokinetic properties. The chiral ethyl moiety of compound 16 provided an unexpected improvement of Wee1 potency. Compound 16, known as ZN-c3, showed excellent in vivo efficacy and is currently being evaluated in phase 2 clinical trials.

Legend

Protein

Chemical

Disease

Primary Citation of related structures